Alcobra to Host Investor Forum and Webcast on March 28 in New York City
March 01, 2017 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, March 01, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system...
Alcobra Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Corporate Update
February 15, 2017 07:00 ET
|
Alcobra Ltd.
Conference Call & Webcast February 15th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time TEL AVIV, Israel, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging...
Alcobra Ltd. to Release Fiscal 2016 Financial Results and Participate at the BIO CEO & Investor Conference in New York
February 08, 2017 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat CNS and cognitive disorders,...
Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD
February 06, 2017 16:01 ET
|
Alcobra Ltd.
Pre-IND meeting held on Alcobra’s proprietary Abuse-Deterrent, Amphetamine Immediate Release (ADAIR) product candidate.Meeting defined a 505(b)(2) development path, to be funded with existing cash...
Alcobra Reports Phase 3 Clinical Trial of MDX in Adults with ADHD Missed Primary Endpoint
January 17, 2017 07:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive...
Alcobra Provides Update on Recent FDA Meeting and Path Forward for MDX Clinical Development Program
January 09, 2017 07:00 ET
|
Alcobra Ltd.
- Alcobra and FDA agree on review of available data from the Phase 3 MEASURE study in a future NDA submission- Top-line results from the MEASURE study to be reported in the coming weeks- FDA to modify...
Alcobra Updates on Recent FDA Meeting
December 14, 2016 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive...
Alcobra Announces Third Quarter 2016 Financial Results and Provides Corporate Update
November 15, 2016 07:30 ET
|
Alcobra Ltd.
Conference Call & Webcast November 15th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time TEL AVIV, Israel, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging...
Alcobra Ltd. to Participate in Upcoming Healthcare Conferences
November 07, 2016 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive...
Alcobra Ltd. to Release Third Quarter Financial Results and Host Corporate Update Conference Call & Webcast on November 15
November 01, 2016 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive...